2016
Metabolic Signature on 18F-FDG PET/CT, HER2 Status, and Survival in Gastric Adenocarcinomas
Celli R, Colunga M, Patel N, Djekidel M, Jain D. Metabolic Signature on 18F-FDG PET/CT, HER2 Status, and Survival in Gastric Adenocarcinomas. Journal Of Nuclear Medicine Technology 2016, 44: 234-238. PMID: 27789750, DOI: 10.2967/jnmt.116.181479.Peer-Reviewed Original ResearchConceptsGastroesophageal junction adenocarcinomaHER2 statusPET/CTHER2 casesF-FDG PET/CTHuman epidermal growth factor 2Metabolic signaturesEpidermal growth factor 2Lymph node metastasisWorse overall survivalHER2-negative casesHistologic signatureOverall survivalGrowth factor 2Junction adenocarcinomaNode metastasisPreoperative parametersTumor histologyGastric adenocarcinomaHER2 overexpressionHigh SUVMedian SUVPathology reportsTumor SUVAggressive form
2011
Genetic Effects and Modifiers of Radiotherapy and Chemotherapy on Survival in Pancreatic Cancer
Zeng H, Yu H, Lu L, Jain D, Kidd MS, Saif MW, Chanock SJ, Hartge P, Risch H. Genetic Effects and Modifiers of Radiotherapy and Chemotherapy on Survival in Pancreatic Cancer. Pancreas 2011, 40: 657-663. PMID: 21487324, PMCID: PMC3116071, DOI: 10.1097/mpa.0b013e31821268d1.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overATP Binding Cassette Transporter, Subfamily G, Member 2ATP-Binding Cassette TransportersCase-Control StudiesConnecticutDihydrouracil Dehydrogenase (NADP)FemaleGenetic MarkersGenetic VariationGenome-Wide Association StudyHumansMaleMiddle AgedNeoplasm ProteinsPancreatic NeoplasmsPolymorphism, Single NucleotidePrognosisProportional Hazards ModelsSerpinsSurvival AnalysisTreatment OutcomeConceptsPancreatic cancerOverall survivalCancer survivalProportional hazards regression modelsSurvival of patientsPopulation-based studyPancreatic cancer survivalHazards regression modelsGerm-line genetic variationEvidence of associationClinical outcomesCancer patientsTreatment outcomesTreatment responseSignificant associationPatientsCancerPrevious genome-wide association study dataRadiotherapyPutative markerGenetic polymorphismsSurvivalDPYD geneChemotherapyEvidence of interaction
2005
Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis
Kakar S, Burgart LJ, Batts KP, Garcia J, Jain D, Ferrell LD. Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis. Modern Pathology 2005, 18: 1417-1423. PMID: 15920538, DOI: 10.1038/modpathol.3800449.Peer-Reviewed Original ResearchConceptsConventional hepatocellular carcinomaFibrolamellar carcinomaHepatocellular carcinomaClinicopathologic featuresOverall survivalTumor sizeMean Ki-67 indexAbsence of cirrhosisDistinct clinicopathologic featuresKi-67 indexMetastatic diseaseLymph nodesOverall mortalityDistant metastasisNonmetastatic casesPathologic featuresAggressive neoplasmNoncirrhotic liverCirrhotic liverCirrhosisKi-67Better outcomesCarcinomaProliferative activityYoung individuals